Histoplasmosis is a fungal infection that arises from the inhalation of spores released by the fungus Histoplasma capsulatum. Our company stands out in the realm of infectious diseases like histoplasmosis, offering a broad spectrum of specialized services designed to address the unique needs of researchers and scientists working in this field.
Overview of Histoplasmosis
This fungal illness is significantly prevalent in various regions across the Americas, with documented cases also arising in parts of Asia and Africa. In areas with the greatest prevalence, histoplasmosis is believed to affect approximately 6.1 individuals per 100,000. Histoplasmosis manifests across a broad spectrum, presenting a variety of symptoms ranging from mild respiratory issues to severe and potentially life-threatening progressive disseminated histoplasmosis.
Fig.1 World map epidemiology of histoplasmosis. (Barros, N., et al., 2023)
Pathogenesis of Histoplasmosis
Histoplasma capsulatum, the causative agent behind histoplasmosis, is a dimorphic fungus capable of existing as a mold in environmental settings and transforming into a yeast form within human tissues. Its propensity to thrive in specific habitats, such as damp soil enriched with bird excreta or bat guano. Inhalation of Histoplasma spores can lead to a spectrum of respiratory symptoms, ranging from mild afflictions to severe systemic complications, particularly in immunocompromised individuals.
Fig.2 Pathogenesis of histoplasmosis. (Barros, N., et al., 2023)
Vaccine and Therapeutic Development for Histoplasmosis
Vaccine of Histoplasmosis
Fungi can exist in different forms that pose challenges for vaccine development. Scientists have been actively researching and investigating potential antigens within Histoplasma that could elicit protective immune responses, such as His 62 and HIS 80.
Therapeutic of Histoplasmosis
Current therapy for histoplasmosis primarily relies on antifungal medications such as amphotericin B. These medications are effective in treating various forms of histoplasmosis, including mild pulmonary infections and severe disseminated cases.
Our Services
With a dedicated focus on infectious diseases, we provide a unique advantage through our integrated platform including infectious disease models, vaccines, and therapeutics development. From access to cutting-edge laboratory facilities and state-of-the-art equipment to a diverse range of high-quality reagents and materials, we aim to advance the research process for our clients.
Vaccine Development Platforms
Therapeutic Development Platforms
Infectious Disease Models
Histoplasmosis can be studied using various animal models to understand the pathogenesis, immune response, and therapy strategies for this fungal infection. Our company offers a variety of animal models for you to accelerate research progress.
Animals are typically infected with Histoplasma through intranasal or intravenous inoculation to mimic natural infection routes. Researchers can study various aspects of the infection such as immune responses and antifungal therapeutics efficacy.
Optional Models: Mouse model inoculated with Histoplasma capsulatum yeast, etc.
By offering a comprehensive suite of services, we empower researchers to foster innovation and breakthroughs in the understanding and management of diseases like histoplasmosis. If you are interested in our services, we invite you to reach out to us for more information and to obtain detailed quotations.
References
- Barros, Nicolas et al. "Pulmonary Histoplasmosis: A Clinical Update." Journal of fungi (Basel, Switzerland) 9.2 (2023): 236.
- Araúz, Ana Belén, and Padmasayee Papineni. "Histoplasmosis." Infectious disease clinics of North America 35.2 (2021): 471-491.
All of our services and products are intended for preclinical research use
only and cannot be used to diagnose, treat or manage patients.
